{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:27:59Z","timestamp":1772166479761,"version":"3.50.1"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,1,9]],"date-time":"2021-01-09T00:00:00Z","timestamp":1610150400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,1,9]],"date-time":"2021-01-09T00:00:00Z","timestamp":1610150400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Parasites Vectors"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Zoonotic visceral leishmaniasis by\n                      <jats:italic>Leishmania infantum<\/jats:italic>\n                      is a first-order pathology in canine veterinary clinics in endemic areas. Moreover, canine infections are considered the main reservoir for human disease; despite their importance in the control of the disease within a One Health approach, no scientometric study has been published. Aims of the study included analyzing the impact of canine leishmaniasis (CanL) on the scientific literature, drugs or combinations used, trends in the period from 2000 to 2020 and efficacy criteria employed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A Web of Science (WOS)-based analysis of publications on CanL and chemotherapy of the disease in the period 2000\u20132020 was carried out using a stepwise methodology. Data were analyzed by year, geographical origin, chemical groups, drugs and combinations, and efficacy criteria.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Reports on CanL (\n                      <jats:italic>n<\/jats:italic>\n                      \u00a0=\u00a03324) represented &lt; 16% of all publications on leishmaniasis (\n                      <jats:italic>n<\/jats:italic>\n                      \u00a0=\u00a020,968), and of these around 18% (\n                      <jats:italic>n<\/jats:italic>\n                      \u00a0=\u00a0596) were related to chemotherapy. Publication records on CanL followed the distribution of the infection by\n                      <jats:italic>L. infantum<\/jats:italic>\n                      in endemic areas although Mediterranean countries were overrepresented in the reports on chemotherapy of CanL. Publications on the main antileishmanial drugs used in clinical practice showed a sustained tendency in the period analyzed. Pentavalent antimonials (Sb\n                      <jats:sup>V<\/jats:sup>\n                      ), alone or in combination with allopurinol, represented &gt; 50% of all publications on chemotherapy of CanL despite the availability of more recently marketed drugs.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      Chemotherapy of CanL still relies on Sb\n                      <jats:sup>V<\/jats:sup>\n                      and combinations and to a lesser extent on miltefosine (MIL). Reports on chemotherapy are scarce and mostly publicly funded, and the variability of experimental conditions hampers the direct comparison of the efficacy of drugs, combinations and schedules. The vast majority of reports on efficacy do not include any information on supportive therapy; this reduces the actual value of the studies if intended for the practical management of the disease. Complete reports on the chemotherapy (etiological\u00a0+\u00a0symptomatic) would add value to the trials performed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Graphical Abstract<\/jats:title>\n                  <\/jats:sec>","DOI":"10.1186\/s13071-020-04544-x","type":"journal-article","created":{"date-parts":[[2021,1,9]],"date-time":"2021-01-09T05:06:49Z","timestamp":1610168809000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Scientometric analysis of chemotherapy of canine leishmaniasis (2000\u20132020)"],"prefix":"10.1186","volume":"14","author":[{"given":"A. I.","family":"Ol\u00edas-Molero","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Font\u00e1n-Matilla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Cuquerella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. M.","family":"Alunda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,1,9]]},"reference":[{"key":"4544_CR1","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1038\/nrmicro1748","volume":"5","author":"F Chappuis","year":"2007","unstructured":"Chappuis F, Sundar S, Hailu A, Ghalib H, Rijal S, Peeling RW, et al. Visceral leishmaniasis: what are the needs for diagnosis, treatment and control? Nat Rev Microbiol. 2007;5:873\u201382.","journal-title":"Nat Rev Microbiol"},{"key":"4544_CR2","doi-asserted-by":"publisher","first-page":"e35671","DOI":"10.1371\/journal.pone.0035671","volume":"7","author":"J Alvar","year":"2012","unstructured":"Alvar J, V\u00e9lez ID, Bern C, Herrero M, Desjeux P, Cano J, et al. Leishmaniasis worldwide and global estimates of its incidence. PLoS ONE. 2012;7:e35671.","journal-title":"PLoS ONE"},{"key":"4544_CR3","unstructured":"WHO. World Health Organization: Leishmaniasis; 2020. http:\/\/www.who.int\/gho\/neglected_diseases\/leishmaniasis\/en\/. Accessed 8 Mar 2020."},{"key":"4544_CR4","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s00436-008-1052-y","volume":"103","author":"TJ Naucke","year":"2008","unstructured":"Naucke TJ, Menn B, Massberg D, Lorentz S. Sandflies and leishmaniasis in Germany. Parasitol Res. 2008;103:65\u20138.","journal-title":"Parasitol Res"},{"key":"4544_CR5","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1016\/j.cvsm.2009.06.008","volume":"39","author":"CA Petersen","year":"2009","unstructured":"Petersen CA, Barr SC. Canine leishmaniasis in North America: emerging or newly recognized? Vet Clin North Am Small Anim Pract. 2009;39:1065\u2013vi.","journal-title":"Vet Clin North Am Small Anim Pract"},{"key":"4544_CR6","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/S1473-3099(08)70043-4","volume":"8","author":"S Antinori","year":"2008","unstructured":"Antinori S, Cascio A, Parravicini C, Bianchi R, Corbellino M. Leishmaniasis among organ transplant recipients. Lancet Infect Dis. 2008;8:191\u20139.","journal-title":"Lancet Infect Dis"},{"key":"4544_CR7","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/S0140-6736(18)31204-2","volume":"392","author":"S Burza","year":"2018","unstructured":"Burza S, Croft SL, Boelaert M. Leishmaniasis. Lancet. 2018;392:951\u201370.","journal-title":"Lancet"},{"key":"4544_CR8","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.vetpar.2007.07.007","volume":"149","author":"F Dantas-Torres","year":"2007","unstructured":"Dantas-Torres F. The role of dogs as reservoirs of Leishmania parasites, with emphasis on Leishmania (Leishmania) infantum and Leishmania (Viannia) braziliensis. Vet Parasitol. 2007;149:139\u201346.","journal-title":"Vet Parasitol"},{"key":"4544_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0065-308X(04)57001-X","volume":"57","author":"J Alvar","year":"2004","unstructured":"Alvar J, Ca\u00f1avate C, Molina R, Moreno J, Nieto J. Canine leishmaniasis. Adv Parasitol. 2004;57:1\u201388.","journal-title":"Adv Parasitol"},{"key":"4544_CR10","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1007\/s004360050164","volume":"82","author":"F Morillas","year":"1996","unstructured":"Morillas F, Rabasco FS, Oca\u00f1a J, Martin-Sanchez J, Oca\u00f1a-Wihelmi J, Acedo C, et al. Leishmaniosis in the focus of the Axarqu\u00eda region, Malaga province, southern Spain: a survey of the human, dog, and vector. Parasitol Res. 1996;82:569\u201370.","journal-title":"Parasitol Res"},{"issue":"1\u20132","key":"4544_CR11","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.vetpar.2015.01.003","volume":"208","author":"L Gradoni","year":"2015","unstructured":"Gradoni L. Canine Leishmania vaccines: Still a long way to go. Vet Parasitol. 2015;208(1\u20132):94\u2013100.","journal-title":"Vet Parasitol"},{"issue":"5","key":"4544_CR12","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1111\/tmi.13382","volume":"25","author":"R V\u00e9lez","year":"2020","unstructured":"V\u00e9lez R, G\u00e1llego M. Commercially approved vaccines for canine leishmaniosis: a review of available data on their safety and efficacy. Trop Med Int Health. 2020;25(5):540\u201357.","journal-title":"Trop Med Int Health"},{"key":"4544_CR13","doi-asserted-by":"publisher","first-page":"e2355","DOI":"10.1371\/journal.pntd.0002355","volume":"7","author":"DNCC Costa","year":"2013","unstructured":"Costa DNCC, Code\u00e7o CT, Silva MA, Werneck GL. Culling dogs in scenarios of imperfect control: realistic impact on the prevalence of canine visceral leishmaniasis. PLoS Negl Trop Dis. 2013;7:e2355.","journal-title":"PLoS Negl Trop Dis"},{"key":"4544_CR14","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.pt.2013.05.003","volume":"29","author":"D Otranto","year":"2013","unstructured":"Otranto D, Dantas-Torres F. The prevention of canine leishmaniasis and its impact on public health. Trends Parasitol. 2013;29:339\u201345.","journal-title":"Trends Parasitol"},{"key":"4544_CR15","doi-asserted-by":"publisher","first-page":"e0162854","DOI":"10.1371\/journal.pone.0162854","volume":"11","author":"AP Sev\u00e1","year":"2016","unstructured":"Sev\u00e1 AP, Ovallos FG, Amaku M, Carrillo E, Moreno J, Galati EAB, et al. Correction: canine-based strategies for prevention and control of visceral leishmaniasis in Brazil. PLoS ONE. 2016;11:e0162854.","journal-title":"PLoS ONE"},{"key":"4544_CR16","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1111\/j.1365-3164.2005.00460.x","volume":"16","author":"C Noli","year":"2005","unstructured":"Noli C, Auxilia ST. Treatment of canine Old World visceral leishmaniasis: a systematic review. Vet Dermatol. 2005;16:213\u201332.","journal-title":"Vet Dermatol"},{"key":"4544_CR17","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1002\/9783527670383.ch2","volume-title":"Trypanosomatid diseases. Molecular routes to drug discovery","author":"MJ Corral-Caridad","year":"2013","unstructured":"Corral-Caridad MJ, Alunda JM. Chemotherapy of leishmaniasis: a veterinary perspective. In: J\u00e4ger T, Koch O, Floh\u00e9 L, editors. Trypanosomatid diseases. Molecular routes to drug discovery. Hoboken: John Wiley & Sons Ltd; 2013. p. 17\u201335."},{"issue":"12","key":"4544_CR18","doi-asserted-by":"publisher","first-page":"e0006052","DOI":"10.1371\/journal.pntd.0006052","volume":"11","author":"A Ponte-Sucre","year":"2017","unstructured":"Ponte-Sucre A, Gamarro F, Dujardin J-C, Barrett MP, L\u00f3pez-V\u00e9lez R, Garc\u00eda-Hern\u00e1ndez R, et al. Drug resistance and treatment failure in leishmaniasis: a 21st century challenge. PLoS Negl Trop Dis. 2017;11(12):e0006052.","journal-title":"PLoS Negl Trop Dis"},{"key":"4544_CR19","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.2460\/javma.236.11.1192","volume":"236","author":"G Oliva","year":"2010","unstructured":"Oliva G, Roura X, Crotti A, Maroli M, Castagnaro M, Gradoni L, et al. Guidelines for treatment of leishmaniasis in dogs. J Am Vet Med Assoc. 2010;236:1192\u20138.","journal-title":"J Am Vet Med Assoc"},{"key":"4544_CR20","doi-asserted-by":"publisher","first-page":"e0006082","DOI":"10.1371\/journal.pntd.0006082","volume":"12","author":"BL Travi","year":"2018","unstructured":"Travi BL, Cordeiro-da-Silva A, Dantas-Torres F, Mir\u00f3 G. Canine visceral leishmaniasis: diagnosis and management of the reservoir living among us. PLoS Negl Trop Dis. 2018;12:e0006082.","journal-title":"PLoS Negl Trop Dis"},{"key":"4544_CR21","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/1756-3305-3-14","volume":"3","author":"K Al-Mutawakel","year":"2010","unstructured":"Al-Mutawakel K, Scutaru C, Shami A, Sakr M, Groneberg DA, Quarcoo D. Scientometric analysis of the world-wide research efforts concerning leishmaniasis. Parasit Vectors. 2010;3:14.","journal-title":"Parasit Vectors"},{"key":"4544_CR22","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/1756-3305-6-55","volume":"6","author":"JM Ramos","year":"2013","unstructured":"Ramos JM, Gonz\u00e1lez-Alcaide G, Bola\u00f1os-Pizarro M. Bibliometric analysis of leishmaniasis research in Medline (1945\u20132010). Parasit Vectors. 2013;6:55.","journal-title":"Parasit Vectors"},{"key":"4544_CR23","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.amsu.2017.12.014","volume":"26","author":"M Soosaraei","year":"2018","unstructured":"Soosaraei M, Khasseh AA, Fakhar M, Hezarjaribi HZ. A decade bibliometric analysis of global research on leishmaniasis in Web of Science database. Ann Med Surg (Lond). 2018;26:30\u20137.","journal-title":"Ann Med Surg (Lond)"},{"key":"4544_CR24","doi-asserted-by":"publisher","first-page":"7","DOI":"10.18800\/educacion.201702.001","volume":"26","author":"DM Cardona-Rom\u00e1n","year":"2017","unstructured":"Cardona-Rom\u00e1n DM, S\u00e1nchez-Torres JM. An\u00e1lisis cienciom\u00e9trico de la producci\u00f3n cient\u00edfica acerca de la investigaci\u00f3n sobre la evaluaci\u00f3n de la implementaci\u00f3n del e-learning en el periodo 2000\u20132015. Educaci\u00f3n. 2017;26:7\u201334.","journal-title":"Educaci\u00f3n"},{"key":"4544_CR25","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s40475-017-0099-1","volume":"4","author":"L Gradoni","year":"2017","unstructured":"Gradoni L. The Leishmaniases of the Mediterranean Region. Curr Trop Med Rep. 2017;4:21\u20136.","journal-title":"Curr Trop Med Rep"},{"key":"4544_CR26","unstructured":"Eurosurveillance Editorial Team. Leishmaniasis in Europe. Eurosurveillance; 2013. https:\/\/www.eurosurveillance.org\/upload\/site-assets\/imgs\/Special_Edition4a.pdf."},{"key":"4544_CR27","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.vetpar.2012.04.028","volume":"189","author":"S Cortes","year":"2012","unstructured":"Cortes S, Vaz Y, Neves R, Maia C, Cardoso L, Campino L. Risk factors for canine leishmaniasis in an endemic Mediterranean region. Vet Parasitol. 2012;189:189\u201396.","journal-title":"Vet Parasitol"},{"key":"4544_CR28","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.tvjl.2014.03.033","volume":"200","author":"MJ Mattin","year":"2014","unstructured":"Mattin MJ, Solano-Gallego L, Dhollander S, Afonso A, Brodbelt DC. The frequency and distribution of canine leishmaniosis diagnosed by veterinary practitioners in Europe. Vet J. 2014;200:410\u20139.","journal-title":"Vet J"},{"key":"4544_CR29","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.prevetmed.2018.10.015","volume":"162","author":"R V\u00e9lez","year":"2019","unstructured":"V\u00e9lez R, Ballart C, Domenech E, Abras A, Fern\u00e1ndez-Ar\u00e9valo A, G\u00f3mez SA, et al. Seroprevalence of canine Leishmania infantum infection in the Mediterranean region and identification of risk factors: the example of North-Eastern and Pyrenean areas of Spain. Prev Vet Med. 2019;162:67\u201375.","journal-title":"Prev Vet Med"},{"key":"4544_CR30","unstructured":"GfK. Pet ownership: Global GfK survey: May 2016. https:\/\/www.gfk.com\/fileadmin\/user_upload\/website_content\/Global_Study\/Documents\/Global-GfK-survey_Pet-Ownership_2016.pdf."},{"key":"4544_CR31","unstructured":"European Medicines Agency: EU\/3\/02\/104; 2003. www.ema.europa.eu\/en\/medicines\/human\/orphan-designations\/eu302104. Accesed 1 Nov 2020"},{"key":"4544_CR32","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1111\/j.1365-3164.2009.00824.x","volume":"20","author":"G Mir\u00f3","year":"2009","unstructured":"Mir\u00f3 G, Oliva G, Cruz I, Ca\u00f1avate C, Mortarino M, Vischer C, et al. Multicentric, controlled clinical study to evaluate effectiveness and safety of miltefosine and allopurinol for canine leishmaniosis. Vet Dermatol. 2009;20:397\u2013404.","journal-title":"Vet Dermatol"},{"key":"4544_CR33","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s00436-009-1404-2","volume":"105","author":"V Woerly","year":"2009","unstructured":"Woerly V, Maynard L, Sanquer A, Eun H-M. Clinical efficacy and tolerance of miltefosine in the treatment of canine leishmaniosis. Parasitol Res. 2009;105:463\u20139.","journal-title":"Parasitol Res"},{"key":"4544_CR34","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s13071-019-3323-0","volume":"12","author":"NF dos Santos","year":"2019","unstructured":"dos Santos NF, Avino VC, Galvis-Ovallos F, Pereira-Chioccola VL, Moreira MAB, Romariz APPL, et al. Use of miltefosine to treat canine visceral leishmaniasis caused by Leishmania infantum in Brazil. Parasit Vectors. 2019;12:79.","journal-title":"Parasit Vectors"},{"key":"4544_CR35","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.drup.2006.04.001","volume":"9","author":"FJ P\u00e9rez-Victoria","year":"2006","unstructured":"P\u00e9rez-Victoria FJ, S\u00e1nchez-Ca\u00f1ete MP, Seifert K, Croft SL, Sundar S, Castanys S, et al. Mechanisms of experimental resistance of Leishmania to miltefosine: Implications for clinical use. Drug Resist Updat. 2006;9:26\u201339.","journal-title":"Drug Resist Updat"},{"key":"4544_CR36","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1186\/s13071-015-0896-0","volume":"8","author":"L Manna","year":"2015","unstructured":"Manna L, Corso R, Galiero G, Cerrone A, Muzj P, Gravino AE. Long-term follow-up of dogs with leishmaniosis treated with meglumine antimoniate plus allopurinol versus miltefosine plus allopurinol. Parasit Vectors. 2015;8:289.","journal-title":"Parasit Vectors"},{"key":"4544_CR37","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.rvsc.2019.01.022","volume":"123","author":"M Marcondes","year":"2019","unstructured":"Marcondes M, Day MJ. Current status and management of canine leishmaniasis in Latin America. Res Vet Sci. 2019;123:261\u201372.","journal-title":"Res Vet Sci"},{"key":"4544_CR38","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1080\/01652176.1997.9694729","volume":"19","author":"RJ Slappendel","year":"1997","unstructured":"Slappendel RJ, Teske E. The effect of intravenous or subcutaneous administration of meglumine antimonate (Glucantime) in dogs with leishmaniasis A randomized clinical trial. Vet Q. 1997;19:10\u20133.","journal-title":"Vet Q"},{"key":"4544_CR39","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1177\/0192623309344088","volume":"37","author":"P Bianciardi","year":"2009","unstructured":"Bianciardi P, Brovida C, Valente M, Aresu L, Cavicchioli L, Vischer C, et al. Administration of miltefosine and meglumine antimoniate in healthy dogs: clinicopathological evaluation of the impact on the kidneys. Toxicol Pathol. 2009;37:770\u20135.","journal-title":"Toxicol Pathol"},{"key":"4544_CR40","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.3390\/molecules14072317","volume":"14","author":"F Fr\u00e9zard","year":"2009","unstructured":"Fr\u00e9zard F, Demicheli C, Ribeiro RR. Pentavalent antimonials: new perspectives for old drugs. Molecules. 2009;14:2317\u201336.","journal-title":"Molecules"},{"key":"4544_CR41","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.ijpddr.2016.04.003","volume":"6","author":"V G\u00f3mez P\u00e9rez","year":"2016","unstructured":"G\u00f3mez P\u00e9rez V, Garc\u00eda-Hernandez R, Corpas-L\u00f3pez V, Tom\u00e1s AM, Mart\u00edn-Sanchez J, Castanys S, et al. Decreased antimony uptake and overexpression of genes of thiol metabolism are associated with drug resistance in a canine isolate of Leishmania infantum. Int J Parasitol Drugs Drug Resist. 2016;6:133\u20139.","journal-title":"Int J Parasitol Drugs Drug Resist"},{"key":"4544_CR42","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/S0304-4017(01)00389-2","volume":"97","author":"JE Valladares","year":"2001","unstructured":"Valladares JE, Riera C, Gonz\u00e1lez-Ensenyat P, D\u00edez-Casc\u00f3n A, Ramos G, Solano-Gallego L, et al. Long term improvement in the treatment of canine leishmaniosis using an antimony liposomal formulation. Vet Parasitol. 2001;97:15\u201321.","journal-title":"Vet Parasitol"},{"key":"4544_CR43","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1128\/AAC.48.1.100-103.2004","volume":"48","author":"C Demicheli","year":"2004","unstructured":"Demicheli C, Ochoa R, da Silva JBB, Falc\u00e3o CAB, Rossi-Bergmann B, de Melo AL, et al. Oral delivery of meglumine antimoniate-\u03b2-cyclodextrin complex for treatment of leishmaniasis. Antimicrob Agents Chemother. 2004;48:100\u20133.","journal-title":"Antimicrob Agents Chemother"},{"key":"4544_CR44","doi-asserted-by":"publisher","first-page":"2564","DOI":"10.1128\/AAC.00223-08","volume":"52","author":"RR Ribeiro","year":"2008","unstructured":"Ribeiro RR, Moura EP, Pimentel VM, Sampaio WM, Silva SM, Schettini DA, et al. Reduced tissue parasitic load and infectivity to sand flies in dogs naturally infected by Leishmania (Leishmania) chagasi following treatment with a liposome formulation of meglumine antimoniate. Antimicrob Agents Chemother. 2008;52:2564\u201372.","journal-title":"Antimicrob Agents Chemother"},{"key":"4544_CR45","first-page":"4","volume":"23","author":"M Roze","year":"2013","unstructured":"Roze M. Canine leishmaniasis\u2014an update. EJCAP Online. 2013;23:4\u201319.","journal-title":"EJCAP Online"},{"key":"4544_CR46","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1097\/01.qco.0000191508.48481.f4","volume":"18","author":"G Barratt","year":"2005","unstructured":"Barratt G, Legrand P. Comparison of the efficacy and pharmacology of formulations of amphotericin B used in treatment of leishmaniasis. Curr Opin Infect Dis. 2005;18:527\u201330.","journal-title":"Curr Opin Infect Dis"},{"key":"4544_CR47","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1086\/507530","volume":"43","author":"C Bern","year":"2006","unstructured":"Bern C, Adler-Moore J, Berenguer J, Boelaert M, den Boer M, Davidson RN, et al. Liposomal amphotericin B for the treatment of visceral leishmaniasis. Clin Infect Dis. 2006;43:917\u201324.","journal-title":"Clin Infect Dis"},{"key":"4544_CR48","doi-asserted-by":"publisher","first-page":"286","DOI":"10.3389\/fmicb.2012.00286","volume":"3","author":"AC Mesa-Arango","year":"2012","unstructured":"Mesa-Arango AC, Scorzoni L, Zaragoza O. It only takes one to do many jobs: Amphotericin B as antifungal and immunomodulatory drug. Front Microbiol. 2012;3:286.","journal-title":"Front Microbiol"},{"key":"4544_CR49","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1128\/AAC.00030-11","volume":"56","author":"B Purkait","year":"2012","unstructured":"Purkait B, Kumar A, Nandi N, Sardar AH, Das S, Kumar S, et al. Mechanism of amphotericin B resistance in clinical isolates of Leishmania donovani. Antimicrob Agents Chemother. 2012;56:1031\u201341.","journal-title":"Antimicrob Agents Chemother"},{"key":"4544_CR50","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1128\/CMR.19.1.111-126.2006","volume":"19","author":"SL Croft","year":"2006","unstructured":"Croft SL, Sundar S, Fairlamb AH. Drug resistance in leishmaniasis. Clin Microbiol Rev. 2006;19:111\u201326.","journal-title":"Clin Microbiol Rev"},{"key":"4544_CR51","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1128\/AAC.41.4.827","volume":"41","author":"F Faraut-Gambarelli","year":"1997","unstructured":"Faraut-Gambarelli F, Piarroux R, Deniau M, Giusiano B, Marty P, Michel G, et al. In vitro and in vivo resistance of Leishmania infantum to meglumine antimoniate: a study of 37 strains collected from patients with visceral leishmaniasis. Antimicrob Agents Chemother. 1997;41:827\u201330.","journal-title":"Antimicrob Agents Chemother"},{"key":"4544_CR52","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1080\/00034983.1992.11812717","volume":"86","author":"M Gramiccia","year":"1992","unstructured":"Gramiccia M, Gradoni L, Orsini S. Decreased sensitivity to meglumine antimoniate (Glucantime) of Leishmania infantum isolated from dogs after several courses of drug treatment. Ann Trop Med Parasitol. 1992;86:613\u201320.","journal-title":"Ann Trop Med Parasitol"},{"issue":"9","key":"4544_CR53","doi-asserted-by":"publisher","first-page":"e0005910","DOI":"10.1371\/journal.pntd.0005910","volume":"11","author":"D Yasur-Landau","year":"2017","unstructured":"Yasur-Landau D, Jaffe CL, Doron-Faigenboim A, David L, Baneth G. Induction of allopurinol resistance in Leishmania infantum isolated from dogs. PLoS Negl Trop Dis. 2017;11(9):e0005910.","journal-title":"PLoS Negl Trop Dis"}],"container-title":["Parasites &amp; Vectors"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13071-020-04544-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13071-020-04544-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13071-020-04544-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,4]],"date-time":"2021-10-04T19:04:08Z","timestamp":1633374248000},"score":1,"resource":{"primary":{"URL":"https:\/\/parasitesandvectors.biomedcentral.com\/articles\/10.1186\/s13071-020-04544-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,9]]},"references-count":53,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["4544"],"URL":"https:\/\/doi.org\/10.1186\/s13071-020-04544-x","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-47685\/v2","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-47685\/v1","asserted-by":"object"}]},"ISSN":["1756-3305"],"issn-type":[{"value":"1756-3305","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,9]]},"assertion":[{"value":"22 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 December 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"36"}}